ACC 2019: Corevalve low-risk TAVR trial - Prof Michael J Reardon & Dr Nicolas van Mieghem
ACC 2019: Corevalve low-risk TAVR trial - Prof Michael J Reardon & Dr Nicolas van MieghemПодробнее
Evolut Low Risk | ACC.19Подробнее
Low Risk TAVR: What the Data Tells Us (Michael J. Reardon, MD) March 26, 2020Подробнее
TAVR: Optimizing the Choice of Prosthesis and Patient (MICHAEL J. REARDON, MD)Подробнее
Live from ACC: Results of the Evolut Low Risk TrialПодробнее
ESC 2019: Wrap-Up - Part 1 - Dr Nicolas Van MieghemПодробнее
TAVR: The Next 3 YearsПодробнее
TAVR and Valve-in-Valve (Michael Reardon, MD)Подробнее
Wrap Up Of ACC 2019: An Analysis Of The Late-Breaking Trials - Dr Nicolas Van MieghemПодробнее
Michael J. Reardon, MD: The TAVR Study for Low-Risk MortalityПодробнее
The CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAVR) SystemПодробнее
ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials | Dr Michael J ReardonПодробнее
N. Van Mieghem | Mechanisms of coronary obstruction during TAVR.Подробнее
The Treatment of Aortic Valve Disease in 2020, A Surgeon’s Perspective (Michael J. Reardon, MD)Подробнее
How I Managed a Difficult CoreValve TAVR Case - Jeffrey Popma, MDПодробнее
ESC 2019: Wrap-Up - Part 2 - Dr Nicolas Van MieghemПодробнее
Michael J. Reardon, MD: Long-Term TAVR PlansПодробнее
PRECISE-TAVI results Prof. Nicolas Van MieghemПодробнее
Wrap Up Of EuroPCR 2019 - An Analysis Of The Late-Breaking TrialsПодробнее